Drug
Firibastat clinical trials
Also written QGC001.
- studies test it
- 10
- open now
- 0
- in phase 3
- 2
- first study started
- 2012
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 4
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Quantum Genomics SA (10)
Studies
Open first, then newest update. How each study uses firibastat is read from its arms, and is right about nine times in ten.
Testing it · 10
- Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular DysfunctionCompletedPhase 2Quantum Genomics SANCT03715998Written as Firibastat
- Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)TerminatedPhase 3Quantum Genomics SANCT04857840Written as Firibastat (QGC001) Period 1
- Firibastat in Treatment-resistant HypertensionCompletedPhase 3Quantum Genomics SANCT04277884Written as Firibastat
- Pharmacokinetics in End Stage Renal Disease PatientsCompletedPhase 1Quantum Genomics SANCT04792333Written as firibastat
- Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet FormulationsCompletedPhase 1Quantum Genomics SANCT03714685Written as Firibastat
- Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic OriginsCompletedPhase 2Quantum Genomics SANCT03198793Written as QGC001
- QUantum Genomics Incremental Dosing in Heart Failure - QUID-HFTerminatedPhase 2Quantum Genomics SANCT02780180Written as QGC001
- Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential HypertensionCompletedPhase 2Quantum Genomics SANCT02322450Written as QGC001
- Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult SubjectsCompletedPhase 1Quantum Genomics SANCT01900184Written as QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
- Phase I Study in Healthy Male Subjects Comparing QGC001 to PlaceboCompletedPhase 1Quantum Genomics SANCT01900171Written as QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
Codes
What other systems call firibastat · ClinicalTrials.gg INT005268
- MeSH (NLM) C528573firibastatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 638KY4573IFIRIBASTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27263587firibastatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166894FiribastatOne source FDA
- DrugBank DB13107One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C528573 | firibastat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 638KY4573I | FIRIBASTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27263587 | firibastat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166894 | Firibastat | One source FDA |
| DrugBank | DB13107 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.